Clinical Update on Hyperlipidemia Management: Advanced Risk Assessment, New Guidelines, and New Treatments to Improve CVD Outcomes
A Live and Live-Streamed Satellite Symposium at the National Lipid Association (NLA) Scientific Sessions
Thursday, June 1st , 2023
Registration and Dinner | 7:15 pm – 7:30 pm ET
CME/CE Symposium | 7:30 pm – 9:00 pm ET
Omni Atlanta Hotel at CNN Center
Grand Ballroom ABCD1
100 CNN Center
Atlanta, GA 30303
Early identification of risk for or development of atherosclerosis with monitoring and management of LDL-C and Lp(a) levels allows enhanced primary and secondary cardiovascular disease prevention. An increased focus on the reduction of atherosclerosis and the prevention of cardiovascular events can reduce the lifetime risk of CVD for the individual patient and also prolong length and quality of life on a population basis, given that cardiovascular disease remains the leading cause of death globally. To accomplish this goal, the healthcare community must keep pace with a growing body of research involving still-novel therapies, such as PCSK9 and siRNA, to lower LDL-C and control atherosclerosis progression. In this program our expert faculty will provide a practical analysis and discussion of recent clinical trial data for these and other newer therapeutics, highlighting management approaches that are currently available and emerging.
I. Recent Advances on the Atherosclerotic Disease Process and Accurate Risk Assessment for Elevated LDL-C and Lp(a) Levels
II. Current Guidelines for Lipid Management to Improve Cardiovascular Outcomes
III. Clinical Trial Data Review for Lipid Lowering Therapies Including siRNA-Based Treatments
IV. Collaborating with the Healthcare Team to Develop Individualized Treatment Plans to Manage Hyperlipidemia and Reduce Cardiovascular Risk
V. Addressing Barriers to Care for Patients with Hyperlipidemia Including Patient Education and Knowledge of Merit-Based Incentive Payment System (MIPS) Programs
This activity is designed to meet the needs of lipid specialists, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, and advance practice registered nurses with an interest in lipid management.
At the conclusion of this activity, participants should be able to:
1. Review recent advances on the atherosclerotic disease process and accurate risk assessment for elevated LDL-C and Lp(a) levels
2. Discuss the details of the most current guidelines for lipid management to improve cardiovascular outcomes
3. Analyze clinical trial data for lipid lowering therapies including siRNA-based treatments
4. Develop strategies for collaboration with the healthcare team to execute individualized treatment plans to manage hyperlipidemia and reduce cardiovascular risk
5. Become proficient at addressing barriers to care for patients with hyperlipidemia including patient education and knowledge of Merit-Based Incentive Payment System (MIPS) programs
Alan S. Brown, MD (Course Chair)
Director, Division of Cardiology
Advocate Lutheran General Hospital
President-Elect, National Lipid Association
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch Medical School
Park Ridge, Illinois
Jessica M. Peña, MD, MPH
Associate Professor of Clinical Medicine
Associate Professor of Medicine in Clinical Radiology
Weill Cornell Medical College
New York, New York
Nataliya Pyslar, MD
John H. Stroger, Jr. Hospital, Provident Hospital
Cook County Health
James A. Underberg, MD, MS
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and AcademicCME. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 AMA PRA Category 1 CreditsTM MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician Credit Designation Statement:
The National Lipid Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Universal Activity Number – JA0007192-9999-23-022-L01-P (Application)
This Activity has been approved for 1.50 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education.
The maximum number of hours awarded for this CE activity is 1.50 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Criteria for Success:
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Americans with Disabilities Act:
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact Nicole McMenamin with AcademicCME prior to the live event at [email protected].
There is no fee for this educational activity.
Supported by an educational grant from Novartis.
This is an independent satellite CME/CE symposium held in conjunction with the 2023 NLA Annual Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.